MedTrace Logo

Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer

NCT05973149 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2023-08-02

No results posted yet for this study

Summary

To evaluate the tolerance, safety, pharmacokinetics, and preliminary anti-tumor activity of QLH12016 in patients with metastatic castration resistant prostate cancer

Conditions

Interventions

DRUG

QLH12016

according to the scheme description

Sponsors & Collaborators

  • Qilu Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Zhisong He, Phd · Department of Urology, Peking University First Hospital

  • Hongqian Guo, Phd · Department of Urology, Drum Tower Hospital, Nanjing University School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-31
Primary Completion
2025-08-31
Completion
2026-01-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05973149 on ClinicalTrials.gov